Fig. 1.

Primary screen with the OICR kinase library for possible novel therapies for LMS. a Flow chart detailing experimental procedure. b The top 10 % of hits from the primary screen is enriched for inhibitors targeting the PI3K/AKT/mTOR pathways. Other hits include cell cycle regulators, such as PLK1 and Wee-1, and RTK inhibitors, such as PDGFR